Catalysts for $NVS
563 tracked
Sep 23, 2025
approval
TRILEPTAL (OXCARBAZEPINE) — FDA approval
OXCARBAZEPINE
→
Sep 23, 2025
approval
TRILEPTAL (OXCARBAZEPINE) — FDA approval
OXCARBAZEPINE
→
Aug 18, 2025
approval
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 6, 2025
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Aug 6, 2025
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Jul 31, 2025
approval
LEQVIO (INCLISIRAN SODIUM) — FDA approval
inclisiran
→
Apr 21, 2025
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Apr 7, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 7, 2025
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Apr 7, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Apr 7, 2025
approval
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Apr 2, 2025
approval
VANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approval
atrasentan hydrochloride
→
Mar 28, 2025
approval
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Mar 28, 2025
approval
PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval
lutetium Lu 177 vipivotide tetraxetan
→
Mar 19, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 19, 2025
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 19, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 19, 2025
approval
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Mar 12, 2025
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Mar 12, 2025
approval
COSENTYX (SECUKINUMAB) — FDA approval
NOVARTIS AG
→
Mar 7, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 7, 2025
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Mar 7, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Mar 7, 2025
approval
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Jan 30, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 30, 2025
approval
TAFINLAR (DABRAFENIB MESYLATE) — FDA approval
dabrafenib mesylate ODT
→
Jan 24, 2025
approval
MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval
Spexotras
→
Jan 24, 2025
approval
MEKINIST (TRAMETINIB) — FDA approval
Spexotras
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→